|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chansky K, Sculier JP, Crowley JJ, Giroux
D, Van Meerbeeck J and Goldstraw P: International Staging Committee
and Participating Institutions: The International Association for
the Study of Lung Cancer Staging Project: Prognostic factors and
pathologic TNM stage in surgically managed non-small cell lung
cancer. J Thorac Oncol. 4:792–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun
W, Han N, Ma Y, Di X, Gao M, et al: Overexpression of osteopontin
is associated with more aggressive phenotypes in human non-small
cell lung cancer. Clin Cancer Res. 11:4646–4652. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han SS, Lee SJ, Kim WJ, Ryu DR, Won JY,
Park S and Cheon MJ: Plasma osteopontin is a useful diagnostic
biomarker for advanced non-small cell lung cancer. Tuberc Respir
Dis (Seoul). 75:104–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang YS, Kim HJ, Chang J, Ahn CM and Kim
SK and Kim SK: Elevated circulating level of osteopontin is
associated with advanced disease state of non-small cell lung
cancer. Lung Cancer. 57:373–380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moszynski R, Szubert S, Szpurek D,
Michalak S and Sajdak S: Role of osteopontin in differential
diagnosis of ovarian tumors. J Obstet Gynaecol Res. 39:1518–1525.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vetrone SA, Montecino-Rodriguez E,
Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC and
Spencer MJ: Osteopontin promotes fibrosis in dystrophic mouse
muscle by modulating immune cell subsets and intramuscular
TGF-beta. J Clin Invest. 119:1583–1594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cho HJ, Cho HJ and Kim HS: Osteopontin: A
multifunctional protein at the crossroads of inflammation,
atherosclerosis, and vascular calcification. Curr Atheroscler Rep.
11:206–213. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lund SA, Giachelli CM and Scatena M: The
role of osteopontin in inflammatory processes. J Cell Commun
Signal. 3:311–322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okyay K, Tavil Y, Sahinarslan A, Tacoy G,
Turfan M, Sen N, Gurbahar O, Boyaci B, Yalcin R, Demirkan D, et al:
Plasma osteopontin levels in prediction of prognosis in acute
myocardial infarction. Acta Cardiol. 66:197–202. 2011.PubMed/NCBI
|
|
12
|
Song G, Ouyang G, Mao Y, Ming Y, Bao S and
Hu T: Osteopontin promotes gastric cancer metastasis by augmenting
cell survival and invasion through Akt-mediated HIF-1alpha
up-regulation and MMP9 activation. J Cell Mol Med. 13(8B):
1706–1718. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu YY, Zhang YY, Lu WF, Mi YJ and Chen YQ:
Prognostic value of osteopontin expression in breast cancer: A
meta-analysis. Mol Clin Oncol. 3:357–362. 2015.PubMed/NCBI
|
|
14
|
Yuan SM, Wang J, Huang HR and Jing H:
Osteopontin expression and its possible functions in the aortic
disorders and coronary artery disease. Rev Bras Cir Cardiovasc.
26:173–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang YD, Chen H, Liu HQ and Hao M:
Correlation between ovarian neoplasm and serum levels of
osteopontin: A meta-analysis. Tumour Biol. 35:11799–11808. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kang CG, Han HJ, Lee HJ, Kim SH and Lee
EO: Rho-associated kinase signaling is required for
osteopontin-induced cell invasion through inactivating cofilin in
human non-small cell lung cancer cell lines. Bioorg Med Chem Lett.
25:1956–1960. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rud AK, Boye K, Oijordsbakken M,
Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A,
Brustugun OT and Mælandsmo GM: Osteopontin is a prognostic
biomarker in non-small cell lung cancer. BMC Cancer. 13:5402013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun BS, Li Y, Zhang ZF, You J and Wang CL:
Osteopontin combined with CD44v6, a novel prognostic biomarker in
non-small cell lung cancer undergoing curative resection. Ann
Thorac Surg. 96:1943–1951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng B, Wang YH, Huang Z, Feng SJ and Wang
YS: Prognostic significance of osteopontin in patients with lung
cancer: A meta-analysis. Int J Clin Exp Med. 7:4616–4626.
2014.PubMed/NCBI
|
|
20
|
Yan CH, Lv M, Li H, Song X, Yan F, Cao S
and Ren X: Osteopontin is a novel prognostic biomarker in
early-stage non-small cell lung cancer after surgical resection. J
Cancer Res Clin Oncol. 141:1371–1378. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karapanagiotou EM, Terpos E, Dilana KD,
Alamara C, Gkiozos I, Polyzos A and Syrigos KN: Serum bone turnover
markers may be involved in the metastatic potential of lung cancer
patients. Med Oncol. 27:332–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou H, Wu T and Zhu Y: The clinical
significance of serum osteopontin in diagnosis of lung cancer. J
Radioimmunol. 24:458–459. 2011.(In Chinese).
|
|
23
|
Jackson D, White IR and Riley RD:
Quantifying the impact of between-study heterogeneity in
multivariate meta-analyses. Stat Med. 31:3805–3820. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peters JL, Sutton AJ, Jones DR, Abrams KR
and Rushton L: Comparison of two methods to detect publication bias
in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zintzaras E and Ioannidis JP: HEGESMA:
Genome search meta-analysis and heterogeneity testing.
Bioinformatics. 21:3672–3673. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song C: Clinical significance of
determination of changes CEA, SA, OPN, and VEGF levels after
operative in patients with lung cancer. Frontier Med. 15:75–76.
2014.
|
|
27
|
Qiu Y and Fu Z: Clinical significance of
determination on serum levels of vascular endothelial growth factor
per platelet count and osteopontin patients with locally advanced
non-small cell lung cancer (unpublished PhD thesis). Hebei Medical
University. Shijiazhuang: R734.2:2012.
|
|
28
|
Xu C, Yu K and Wang Q: The levels and
clinical significance of osteopontin in serum of patients with lung
cancer. J Chin Physician. 14:179–181. 2012.
|
|
29
|
Karadag F, Gulen ST, Karul AB, Kilicarslan
N, Ceylan E, Kuman NK and Cildag O: Osteopontin as a marker of
weight loss in lung cancer. Scand J Clin Lab Invest. 71:690–694.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blasberg JD, Pass HI, Goparaju CM, Flores
RM, Lee S and Donington JS: Reduction of elevated plasma
osteopontin levels with resection of non-small-cell lung cancer. J
Clin Oncol. 28:936–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin M and Zhang J: Study on OPN levels of
serum in non-small cell lung cancer. Ningxia Med J. 31:679–680.
2009.
|
|
32
|
Dong S, Shao Z, Pan Y, Dai J and Chen G:
The clinical significance of detection of serum osteopontin in
patient with lung cancer. Mod J Integr Tradit Chin West Med.
17:3740–3741. 2008.
|
|
33
|
Weng W and Fu C: Value of serum
osteopontin determination in patient with lung carcinoma. Lab Med
Clin. 4:1025–1026. 2007.
|
|
34
|
Fedarko NS, Jain A, Karadag A, Van Eman MR
and Fisher LW: Elevated serum bone sialoprotein and osteopontin in
colon, breast, prostate, and lung cancer. Clin Cancer Res.
7:4060–4066. 2001.PubMed/NCBI
|
|
35
|
Chambers AF and Vanderhyden BC: Ovarian
cancer biomarkers in urine. Clin Cancer Res. 12:323–327. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin CK, Chao TK, Lai HC and Lee HS: LMX1A
as a prognostic marker in ovarian mucinous cystadenocarcinoma. Am J
Clin Pathol. 137:971–977. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu TT, Han ZG, Shan L, Tao J, Zhang T,
Yuan SF and Shen HL: Expression of osteopontin in non-small cell
lung cancer and correlative relation with microvascular density.
Asian Pac J Cancer Prev. 15:29–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Štemberger C, Matušan-Ilijaš K, Avirović
M, Bulat-Kardum L, Ivančić A, Jonjić N and Lučin K: Osteopontin is
associated with decreased apoptosis and αv integrin expression in
lung adenocarcinoma. Acta Histochem. 116:222–229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun BS, You J, Li Y, Zhang ZF and Wang CL:
Osteopontin knockdown suppresses non-small cell lung cancer cell
invasion and metastasis. Chin Med J (Engl). 126:1683–1688.
2013.PubMed/NCBI
|
|
40
|
Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ,
Ling XL and Ma SC: The prognostic value of osteopontin expression
in non-small cell lung cancer: A meta-analysis. J Mol Histol.
45:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
